What is the definition of fibroadenosis (fibrocystic breast disease) in a reproductive-age female patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Definition of Fibroadenosis (Fibrocystic Breast Disease)

Fibroadenosis, also known as fibrocystic breast disease or fibrocystic changes, is a benign breast condition classified as a nonproliferative lesion characterized by adenosis, fibrosis, and cyst formation in the breast tissue. 1

Pathophysiologic Characteristics

  • The condition results from estrogen predominance and progesterone deficiency, leading to hyperproliferation of connective tissue (fibrosis) followed by epithelial proliferation 2
  • Fibrocystic changes are believed to be associated with fluctuating hormone levels and are predominantly found in premenopausal women due to higher estrogen levels 3
  • The disease progresses with advancing premenopausal age and is most pronounced in women during their 40s, with regression typically occurring during the postmenopausal period 2

Classification Within Benign Breast Disease

  • According to the American College of Radiology, benign breast disease is classified into three broad categories: nonproliferative lesions, proliferative lesions without atypia, and proliferative lesions with atypia 1
  • Fibrocystic changes are specifically categorized as nonproliferative lesions, along with benign calcifications, fibroadenomas, lipomas, fat necrosis, and nonsclerosing adenosis 1

Clinical Presentation

  • The clinical manifestations include breast and axillary pain or tenderness, development of fibrocystic plaques, nodularity, macrocysts, and fibrocystic lumps 2
  • Patients present with breast pain, lumpiness, or cysts as the characteristic features 4
  • The condition afflicts at least 50% of women of childbearing age, making it extremely common 5

Imaging and Diagnostic Features

  • On ultrasound and mammography, fibrocystic changes appear as benign findings and are classified as BI-RADS Category 2 (benign finding) 1
  • Simple cysts associated with fibrocystic changes are placed in BI-RADS Category 2, essentially indicating a report that is negative for malignancy 1
  • Complex cysts and clustered microcysts may be classified as BI-RADS Category 3 (probably benign) requiring short-interval follow-up 1

Cancer Risk Implications

  • Nonproliferative lesions like fibrocystic changes are independent risk factors for developing breast cancer, though the risk is lower compared to proliferative lesions 1
  • Almost 30% of women with breast cancer have a history of benign breast disease 1
  • The risk of breast cancer is increased twofold to fourfold in patients with fibrocystic disease, particularly when atypia is present on biopsy 2, 4

Important Clinical Distinction

  • Fibrocystic changes must be distinguished from complex fibroadenoma, which includes sclerosing adenosis, papillary apocrine metaplasia, epithelial calcifications, and/or cysts greater than 3 mm 6
  • Extensive cystic degeneration in a fibroadenoma (cystic fibroadenoma) is very rare and requires differentiation from other cystic lesions including cystic papilloma 6

Hormonal Associations

  • Certain conditions causing hormonal imbalances, such as polycystic ovarian syndrome, are associated with increased risk of fibrocystic changes 3
  • Fibrocystic changes can occur in postmenopausal women on hormonal replacement therapy but are otherwise extremely rare in this population 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fibrocystic breast disease.

American family physician, 1987

Research

Fibrocystic breast disease. An update and review.

Journal of obstetric, gynecologic, and neonatal nursing : JOGNN, 1990

Research

Cystic fibroadenoma of the breast: a case report.

Turk patoloji dergisi, 2011

Related Questions

What is the management approach for a patient with fibrocystic changes, usual ductal hyperplasia, adenosis, and apocrine metaplasia, negative for atypia?
What could be causing the breast changes I experience when I put my arm on my waist, possibly related to fibrocystic changes or other conditions, as a female of reproductive or postmenopausal age?
What is the most likely diagnosis and next step in management for a 32-year-old female, gravida (number of times pregnant) 1, para (number of viable births) 1, presenting with a 3-day onset of painful bumps in bilateral breasts around her menstrual cycle?
Can fibrocystic changes of the breast occur during perimenopause?
What are the recommended contraceptive options for patients with fibrocystic breast changes?
How to manage elevated Creatine Kinase (CK) levels in a patient with Chronic Kidney Disease (CKD)?
What are the appropriate steps for diagnosing and managing a hypertrophic scar in a 15-40 year old patient with a history of injury?
What is the best course of action for a patient with acute hypertension and pressure behind the eye, potentially with a history of migraine or other headache disorders?
What stool testing is recommended for a pediatric patient presenting with symptoms suggestive of irritable bowel syndrome (IBS)?
What is the origin of fibrocystic breast disease in a reproductive-age female patient?
What is the best course of treatment for a patient with suspected labile hypertension related to autonomic dysfunction and adrenergic response, characterized by normal or borderline blood pressure at rest, episodic hypertension during stress or incorrect posture, and reactive tachycardia that improves with rest and breathing, with normal electrocardiogram (ECG) results?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.